Review



percpconjugated tlr7  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    R&D Systems percpconjugated tlr7
    Figure 6. Cytokine production and TLRs in response to plasma exosomes. (a) PBMCs were treated with the TLR3 inhibitor (10 µM) for 30 min or remained untreated, followed by stimulation with plasma exosomes (4 × 109 ml−1) for 16 h. Production of cytokines was determined by flow cytometry gated on CD4+, CD8+, and CD14+. COV exo, COVID-19 plasma exosome treatment; inh/cov, TLR3 inhibitor treated and COVID-19 plasma exosomes stimulated; non-COV, treatment with non-COVID plasma exosomes. *p < 0.05; ns, p > 0.05. ANOVA, equal variants. (b) CD4+ T cells, CD8+ T cells, and CD14+ monocytes were isolated from PBMC using MicroBeads, followed by treatment with plasma exosomes from COVID-19 patients upon admission (COV exo, 4 × 109 ml−1), non-COVID donors (non- COV exo, 4 × 109 ml−1), or poly(I:C) (5 µg ml−1) for 16 h at 37 °C. Expression of TLR3, <t>TLR7,</t> TLR8, and TLR9 was determined by flow cytometry gated on live cells. Isotype antibodies and no-antibody blanks were used in each flow cytometry assay. ctrl, medium only control. Error bars, ± SD; *p < 0.05; ns, p > 0.05; one-way ANOVA. Isotype antibody controls and blank controls were performed in parallel in flow cytometry.
    Percpconjugated Tlr7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/percpconjugated+tlr7/Human+TLR7+PerCP-conjugated+Antibody/pm36526691-308-62-66
    Average 92 stars, based on 3 article reviews
    percpconjugated tlr7 - by Bioz Stars, 2026-10
    92/100 stars

    Images

    1) Product Images from "COVID-19 plasma exosomes promote proinflammatory immune responses in peripheral blood mononuclear cells."

    Article Title: COVID-19 plasma exosomes promote proinflammatory immune responses in peripheral blood mononuclear cells.

    Journal: Scientific reports

    doi: 10.1038/s41598-022-26457-8

    Figure 6. Cytokine production and TLRs in response to plasma exosomes. (a) PBMCs were treated with the TLR3 inhibitor (10 µM) for 30 min or remained untreated, followed by stimulation with plasma exosomes (4 × 109 ml−1) for 16 h. Production of cytokines was determined by flow cytometry gated on CD4+, CD8+, and CD14+. COV exo, COVID-19 plasma exosome treatment; inh/cov, TLR3 inhibitor treated and COVID-19 plasma exosomes stimulated; non-COV, treatment with non-COVID plasma exosomes. *p < 0.05; ns, p > 0.05. ANOVA, equal variants. (b) CD4+ T cells, CD8+ T cells, and CD14+ monocytes were isolated from PBMC using MicroBeads, followed by treatment with plasma exosomes from COVID-19 patients upon admission (COV exo, 4 × 109 ml−1), non-COVID donors (non- COV exo, 4 × 109 ml−1), or poly(I:C) (5 µg ml−1) for 16 h at 37 °C. Expression of TLR3, TLR7, TLR8, and TLR9 was determined by flow cytometry gated on live cells. Isotype antibodies and no-antibody blanks were used in each flow cytometry assay. ctrl, medium only control. Error bars, ± SD; *p < 0.05; ns, p > 0.05; one-way ANOVA. Isotype antibody controls and blank controls were performed in parallel in flow cytometry.
    Figure Legend Snippet: Figure 6. Cytokine production and TLRs in response to plasma exosomes. (a) PBMCs were treated with the TLR3 inhibitor (10 µM) for 30 min or remained untreated, followed by stimulation with plasma exosomes (4 × 109 ml−1) for 16 h. Production of cytokines was determined by flow cytometry gated on CD4+, CD8+, and CD14+. COV exo, COVID-19 plasma exosome treatment; inh/cov, TLR3 inhibitor treated and COVID-19 plasma exosomes stimulated; non-COV, treatment with non-COVID plasma exosomes. *p < 0.05; ns, p > 0.05. ANOVA, equal variants. (b) CD4+ T cells, CD8+ T cells, and CD14+ monocytes were isolated from PBMC using MicroBeads, followed by treatment with plasma exosomes from COVID-19 patients upon admission (COV exo, 4 × 109 ml−1), non-COVID donors (non- COV exo, 4 × 109 ml−1), or poly(I:C) (5 µg ml−1) for 16 h at 37 °C. Expression of TLR3, TLR7, TLR8, and TLR9 was determined by flow cytometry gated on live cells. Isotype antibodies and no-antibody blanks were used in each flow cytometry assay. ctrl, medium only control. Error bars, ± SD; *p < 0.05; ns, p > 0.05; one-way ANOVA. Isotype antibody controls and blank controls were performed in parallel in flow cytometry.

    Techniques Used: Clinical Proteomics, Flow Cytometry, Isolation, Expressing, Control

    Related Articles

    Flow Cytometry:

    Article Title: COVID-19 plasma exosomes promote proinflammatory immune responses in peripheral blood mononuclear cells.
    Article Snippet: Poly(I:C) treated with RNase A (ThermoFisher Sci., Waltham, MA) at 37 °C for 30 min was used as a negative control for poly(I:C) treatment. .. For flow cytometry, cells were stained using monoclonal antibodies: PE-conjugated IL-6 (Clone MQ2-13A5, BD Biosciences, Franklin Lakes, NJ), APC-conjugated TNF-α (Clone MAb11, BD Biosciences), PE-CF594-conjugated IL-8 (Clone G265-8, BD Biosciences), PE-CF594-conjugated IL-10 (Clone JES3-19F1, BD Biosciences), APC-R700-conjugated IL-17 (Clone N49-653, BD Biosciences), PerCP-Cy5.5-conjugated IFNγ (Clone B27, BD Biosciences), PerCP-Cy5.5-conjugated TGFβ (Clone TW4-9E7, BD Biosciences), PE-conjugated TLR3 (Clone TLR-104, Biolegend, San Diego, CA), PerCPconjugated TLR7 (Clone 533707, R&D systems), FITC anti-human CD288 (TLR8) antibody (Clone 16018A, Biolegend), and APC-conjugated TLR9 (Clone S16D, Biolegend). .. Isotype control antibodies were APC mouse IgG1 (Clone MOPC-21), PE-CF594 mouse IgG2b (Clone 27–35), APC-R700 mouse IgG1 (Clone X40), PerCPCy5.5 mouse IgG1 (Clone X40), PE mouse IgG2a (Clone MOPC-173), and PerCP mouse IgG2a (Clone X39) from BD Biosciences.

    Staining:

    Article Title: COVID-19 plasma exosomes promote proinflammatory immune responses in peripheral blood mononuclear cells.
    Article Snippet: Poly(I:C) treated with RNase A (ThermoFisher Sci., Waltham, MA) at 37 °C for 30 min was used as a negative control for poly(I:C) treatment. .. For flow cytometry, cells were stained using monoclonal antibodies: PE-conjugated IL-6 (Clone MQ2-13A5, BD Biosciences, Franklin Lakes, NJ), APC-conjugated TNF-α (Clone MAb11, BD Biosciences), PE-CF594-conjugated IL-8 (Clone G265-8, BD Biosciences), PE-CF594-conjugated IL-10 (Clone JES3-19F1, BD Biosciences), APC-R700-conjugated IL-17 (Clone N49-653, BD Biosciences), PerCP-Cy5.5-conjugated IFNγ (Clone B27, BD Biosciences), PerCP-Cy5.5-conjugated TGFβ (Clone TW4-9E7, BD Biosciences), PE-conjugated TLR3 (Clone TLR-104, Biolegend, San Diego, CA), PerCPconjugated TLR7 (Clone 533707, R&D systems), FITC anti-human CD288 (TLR8) antibody (Clone 16018A, Biolegend), and APC-conjugated TLR9 (Clone S16D, Biolegend). .. Isotype control antibodies were APC mouse IgG1 (Clone MOPC-21), PE-CF594 mouse IgG2b (Clone 27–35), APC-R700 mouse IgG1 (Clone X40), PerCPCy5.5 mouse IgG1 (Clone X40), PE mouse IgG2a (Clone MOPC-173), and PerCP mouse IgG2a (Clone X39) from BD Biosciences.

    Bioprocessing:

    Article Title: COVID-19 plasma exosomes promote proinflammatory immune responses in peripheral blood mononuclear cells.
    Article Snippet: Poly(I:C) treated with RNase A (ThermoFisher Sci., Waltham, MA) at 37 °C for 30 min was used as a negative control for poly(I:C) treatment. .. For flow cytometry, cells were stained using monoclonal antibodies: PE-conjugated IL-6 (Clone MQ2-13A5, BD Biosciences, Franklin Lakes, NJ), APC-conjugated TNF-α (Clone MAb11, BD Biosciences), PE-CF594-conjugated IL-8 (Clone G265-8, BD Biosciences), PE-CF594-conjugated IL-10 (Clone JES3-19F1, BD Biosciences), APC-R700-conjugated IL-17 (Clone N49-653, BD Biosciences), PerCP-Cy5.5-conjugated IFNγ (Clone B27, BD Biosciences), PerCP-Cy5.5-conjugated TGFβ (Clone TW4-9E7, BD Biosciences), PE-conjugated TLR3 (Clone TLR-104, Biolegend, San Diego, CA), PerCPconjugated TLR7 (Clone 533707, R&D systems), FITC anti-human CD288 (TLR8) antibody (Clone 16018A, Biolegend), and APC-conjugated TLR9 (Clone S16D, Biolegend). .. Isotype control antibodies were APC mouse IgG1 (Clone MOPC-21), PE-CF594 mouse IgG2b (Clone 27–35), APC-R700 mouse IgG1 (Clone X40), PerCPCy5.5 mouse IgG1 (Clone X40), PE mouse IgG2a (Clone MOPC-173), and PerCP mouse IgG2a (Clone X39) from BD Biosciences.



    Similar Products

    percpconjugated tlr7  (R&D Systems)
    92
    R&D Systems percpconjugated tlr7
    Figure 6. Cytokine production and TLRs in response to plasma exosomes. (a) PBMCs were treated with the TLR3 inhibitor (10 µM) for 30 min or remained untreated, followed by stimulation with plasma exosomes (4 × 109 ml−1) for 16 h. Production of cytokines was determined by flow cytometry gated on CD4+, CD8+, and CD14+. COV exo, COVID-19 plasma exosome treatment; inh/cov, TLR3 inhibitor treated and COVID-19 plasma exosomes stimulated; non-COV, treatment with non-COVID plasma exosomes. *p < 0.05; ns, p > 0.05. ANOVA, equal variants. (b) CD4+ T cells, CD8+ T cells, and CD14+ monocytes were isolated from PBMC using MicroBeads, followed by treatment with plasma exosomes from COVID-19 patients upon admission (COV exo, 4 × 109 ml−1), non-COVID donors (non- COV exo, 4 × 109 ml−1), or poly(I:C) (5 µg ml−1) for 16 h at 37 °C. Expression of TLR3, <t>TLR7,</t> TLR8, and TLR9 was determined by flow cytometry gated on live cells. Isotype antibodies and no-antibody blanks were used in each flow cytometry assay. ctrl, medium only control. Error bars, ± SD; *p < 0.05; ns, p > 0.05; one-way ANOVA. Isotype antibody controls and blank controls were performed in parallel in flow cytometry.
    Percpconjugated Tlr7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/percpconjugated+tlr7/Human+TLR7+PerCP-conjugated+Antibody/pm36526691-308-62-66
    Average 92 stars, based on 1 article reviews
    percpconjugated tlr7 - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 6. Cytokine production and TLRs in response to plasma exosomes. (a) PBMCs were treated with the TLR3 inhibitor (10 µM) for 30 min or remained untreated, followed by stimulation with plasma exosomes (4 × 109 ml−1) for 16 h. Production of cytokines was determined by flow cytometry gated on CD4+, CD8+, and CD14+. COV exo, COVID-19 plasma exosome treatment; inh/cov, TLR3 inhibitor treated and COVID-19 plasma exosomes stimulated; non-COV, treatment with non-COVID plasma exosomes. *p < 0.05; ns, p > 0.05. ANOVA, equal variants. (b) CD4+ T cells, CD8+ T cells, and CD14+ monocytes were isolated from PBMC using MicroBeads, followed by treatment with plasma exosomes from COVID-19 patients upon admission (COV exo, 4 × 109 ml−1), non-COVID donors (non- COV exo, 4 × 109 ml−1), or poly(I:C) (5 µg ml−1) for 16 h at 37 °C. Expression of TLR3, TLR7, TLR8, and TLR9 was determined by flow cytometry gated on live cells. Isotype antibodies and no-antibody blanks were used in each flow cytometry assay. ctrl, medium only control. Error bars, ± SD; *p < 0.05; ns, p > 0.05; one-way ANOVA. Isotype antibody controls and blank controls were performed in parallel in flow cytometry.

    Journal: Scientific reports

    Article Title: COVID-19 plasma exosomes promote proinflammatory immune responses in peripheral blood mononuclear cells.

    doi: 10.1038/s41598-022-26457-8

    Figure Lengend Snippet: Figure 6. Cytokine production and TLRs in response to plasma exosomes. (a) PBMCs were treated with the TLR3 inhibitor (10 µM) for 30 min or remained untreated, followed by stimulation with plasma exosomes (4 × 109 ml−1) for 16 h. Production of cytokines was determined by flow cytometry gated on CD4+, CD8+, and CD14+. COV exo, COVID-19 plasma exosome treatment; inh/cov, TLR3 inhibitor treated and COVID-19 plasma exosomes stimulated; non-COV, treatment with non-COVID plasma exosomes. *p < 0.05; ns, p > 0.05. ANOVA, equal variants. (b) CD4+ T cells, CD8+ T cells, and CD14+ monocytes were isolated from PBMC using MicroBeads, followed by treatment with plasma exosomes from COVID-19 patients upon admission (COV exo, 4 × 109 ml−1), non-COVID donors (non- COV exo, 4 × 109 ml−1), or poly(I:C) (5 µg ml−1) for 16 h at 37 °C. Expression of TLR3, TLR7, TLR8, and TLR9 was determined by flow cytometry gated on live cells. Isotype antibodies and no-antibody blanks were used in each flow cytometry assay. ctrl, medium only control. Error bars, ± SD; *p < 0.05; ns, p > 0.05; one-way ANOVA. Isotype antibody controls and blank controls were performed in parallel in flow cytometry.

    Article Snippet: For flow cytometry, cells were stained using monoclonal antibodies: PE-conjugated IL-6 (Clone MQ2-13A5, BD Biosciences, Franklin Lakes, NJ), APC-conjugated TNF-α (Clone MAb11, BD Biosciences), PE-CF594-conjugated IL-8 (Clone G265-8, BD Biosciences), PE-CF594-conjugated IL-10 (Clone JES3-19F1, BD Biosciences), APC-R700-conjugated IL-17 (Clone N49-653, BD Biosciences), PerCP-Cy5.5-conjugated IFNγ (Clone B27, BD Biosciences), PerCP-Cy5.5-conjugated TGFβ (Clone TW4-9E7, BD Biosciences), PE-conjugated TLR3 (Clone TLR-104, Biolegend, San Diego, CA), PerCPconjugated TLR7 (Clone 533707, R&D systems), FITC anti-human CD288 (TLR8) antibody (Clone 16018A, Biolegend), and APC-conjugated TLR9 (Clone S16D, Biolegend).

    Techniques: Clinical Proteomics, Flow Cytometry, Isolation, Expressing, Control